Suppr超能文献

急性肾损伤是否会影响需要体外膜肺氧合的急性呼吸窘迫综合征成年患者的生存率?

Does acute kidney injury affect survival in adults with acute respiratory distress syndrome requiring extracorporeal membrane oxygenation?

作者信息

Devasagayaraj Richard, Cavarocchi Nicholas C, Hirose Hitoshi

机构信息

Department of Surgery, Thomas Jefferson University, Philadelphia, PA.

出版信息

Perfusion. 2018 Jul;33(5):375-382. doi: 10.1177/0267659118755272. Epub 2018 Jan 23.

Abstract

INTRODUCTION

Patients who develop severe acute respiratory distress syndrome (ARDS) despite full medical management may require veno-venous extracorporeal membrane oxygenation (VV ECMO) to support respiratory function. Survival outcomes remain unclear in those who develop acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT) during VV ECMO for isolated severe respiratory failure in adult populations.

METHODS

A retrospective chart review (2010-2016) of patients who underwent VV ECMO for ARDS was conducted with university institutional review board (IRB) approval. Patients supported by veno-arterial ECMO were excluded. AKI was defined by acute renal failure receiving CRRT and the outcomes of patients on VV ECMO were compared between the AKI and non-AKI groups.

RESULTS

We identified 54 ARDS patients supported by VV ECMO (mean ECMO days 12 ± 6.7) with 16 (30%) in the AKI group and 38 (70%) in the non-AKI group. No patient had previous renal failure and the serum creatinine was not significantly different between the two groups at the time of ECMO initiation. The AKI group showed a greater incidence of complications during ECMO, including liver failure (38% vs. 5%, p=0.002) and hemorrhage (94% vs. 45%, p=0.0008). ECMO survival of the AKI group (56% [9/16]) was inferior to the non-AKI group (87% [33/38], p=0.014).

CONCLUSIONS

Our study demonstrated that VV ECMO successfully manages patients with severe isolated lung injury. However, once patients develop AKI during VV ECMO, they are likely to further develop multi-organ dysfunction, including hepatic and hematological complications, leading to inferior survival.

摘要

引言

尽管接受了全面的药物治疗,但仍发展为严重急性呼吸窘迫综合征(ARDS)的患者可能需要静脉-静脉体外膜肺氧合(VV ECMO)来支持呼吸功能。对于成年人群中因单纯严重呼吸衰竭在VV ECMO期间发生急性肾损伤(AKI)并需要持续肾脏替代治疗(CRRT)的患者,其生存结果仍不明确。

方法

在大学机构审查委员会(IRB)批准下,对因ARDS接受VV ECMO治疗的患者进行了回顾性病历审查(2010 - 2016年)。排除接受静脉-动脉ECMO支持的患者。AKI定义为接受CRRT的急性肾衰竭,并比较AKI组和非AKI组接受VV ECMO治疗患者的结局。

结果

我们确定了54例接受VV ECMO支持的ARDS患者(平均ECMO天数12±6.7天),其中AKI组16例(30%),非AKI组38例(70%)。所有患者既往均无肾衰竭,在开始ECMO时两组血清肌酐无显著差异。AKI组在ECMO期间并发症发生率更高,包括肝功能衰竭(38%对5%,p = 0.002)和出血(94%对45%,p = 0.0008)。AKI组的ECMO生存率(56% [9/16])低于非AKI组(87% [33/38],p = 0.014)。

结论

我们的研究表明,VV ECMO成功治疗了严重单纯性肺损伤患者。然而,一旦患者在VV ECMO期间发生AKI,他们可能会进一步发展为多器官功能障碍,包括肝脏和血液学并发症,导致生存率降低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验